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OBJECTIVES This study was done to elucidate the effects of interleukin (IL)-1 gene polymorphisms on
coronary artery disease (CAD) associated with Chlamydia pneumoniae (CP) infection.
BACKGROUND It was suggested that CP was associated with CAD. However, genetic factors involved in
CAD associated with CP infection are unknown.
METHODS We evaluated CP immunoglobulin G (IgG) seropositivity and IL-1b (a C/T transition at
2511) and IL-1 receptor antagonist (IL-1Ra) (a variable-number repeat in intron 2) gene
polymorphisms in 292 patients undergoing coronary angiography.
RESULTS Seropositivity for CP was present in 61% of patients with CAD versus 51% without CAD
(p 5 NS). The percentage of patients having IL-1b (2511) C/C genotype and/or IL-1Ra
(intron 2) 2- or 3-repeat allele was higher in patients with CAD than without CAD (29 vs.
16%, p , 0.025). To clarify the effects of these CAD-associated variants (IL-1b C/C and/or
IL-1Ra 2- or 3-repeat), patients were divided into four groups. A stepwise increase in CAD
prevalence was observed depending on CP seropositivity and the variants. Odds ratios (ORs)
for CAD were 1.4 in the group with seropositivity alone, 1.7 with the variants alone and 3.8
with seropositivity and the variants. Such variants were associated with CAD in both patients
with and without seropositivity. Interestingly, high prevalence of myocardial infarction (MI)
was confined to the group with seropositivity and the variants (OR, 2.8). The variants were
associated with MI only in patients with CP seropositivity.
CONCLUSIONS The IL-1 gene polymorphisms were found to play a role in the development of CAD,
especially MI, in patients with CP infection. (J Am Coll Cardiol 2001;38:712–7) © 2001 by
the American College of Cardiology
Recently, inflammation was suggested to be involved in the
pathogenesis of atherosclerosis (1). Infectious agents cause
inflammation and may play a role in the development of
coronary artery disease (CAD). Chlamydia pneumoniae
(CP), one of the common human respiratory pathogens,
was frequently reported to be associated with CAD (2–4).
However, the potential contribution of CP to CAD is still
a matter of debate. Recent prospective studies failed to show
any association between CP infection and CAD (5,6). The
inflammatory response to CP infection may vary from
person to person, and only a small number of individuals
develop CAD.
Although CAD is known to have a genetic basis (7–9),
genetic factors involved in CAD associated with CP infec-
tion are unknown. Interleukin (IL)-1b and IL-1 receptor
antagonist (IL-1Ra), which are both cytokines to mediate
inflammation, are likely involved in the pathogenesis of
CAD (10–12). Recently, a polymorphism of the IL-1b
gene (a C/T transition at position 2511) and one of the
IL-1Ra gene (a variable-number tandem repeat in intron 2)
were reported to be associated with CAD (13,14). We
hypothesized that these IL-1 gene polymorphisms may have
some effects on the development of CAD associated with
CP infection.
METHODS
Study subjects. The IL-1b and IL-1Ra gene polymor-
phisms as well as CP immunoglobulin G (IgG) seroposi-
tivity were investigated in 292 consecutive patients who
underwent coronary angiography for suspected CAD at
National Defense Medical College Hospital from July 1999
to December 2000. Our study was approved by the Ethics
Committee of the hospital. After admission, written in-
formed consent was obtained, and blood samples were taken
in a fasting state. Coronary angiograms were evaluated blind
to the genotype data. Coronary artery disease was defined as
at least one coronary artery having .50% luminal diameter
stenosis. Myocardial infarction (MI) was confirmed by the
documentation of coronary artery stenosis plus either eleva-
tions of cardiac enzymes or diagnostic changes on electro-
cardiograms. Any patients who had coronary artery bypass
grafting were excluded, but 32 patients who had previously
undergone percutaneous transluminal coronary angioplasty
were included.
Serology and genotyping. The cutoff index of serum
CP-specific IgG titer was measured by an enzyme-linked
immunosorbent assay (ELISA) using a commercially avail-
able kit (HITAZYME C. pneumoniae, Hitachi Chemical,
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Tokyo, Japan). This ELISA used the CP outer membrane
complex as a CP-specific antigen. The cutoff index of $1.10
was considered seropositive.
We analyzed a polymorphism of the IL-1b gene (a C/T
base transition at 2511 in the promoter region) and one of
the IL-1Ra gene (variable numbers of an 86-bp tandem
repeat in intron 2). Genomic DNA was extracted from
blood. Genotyping was performed by polymerase chain
reaction (PCR)-base methods as previously reported
(15,16). Briefly, the region containing the IL-1b polymor-
phic site was amplified by PCR, and a restriction fragment-
length polymorphism analysis was performed after AvaI
digestion (15). The region containing the IL-1Ra polymor-
phic site was also amplified by PCR, and this product was
directly analyzed by electrophoresis on a 2% agarose gel
stained with ethidium bromide (16).
Statistical analysis. Any differences among the groups of
patients were evaluated by the unpaired t test and analysis of
variance with the Scheffe´ test for continuous variables and
by the chi-square test for categorical variables. Forward
stepwise multiple logistic regression analysis was used to
elucidate the associations of CP seropositivity and IL-1
gene polymorphisms with CAD. A p value of ,0.05 was
considered to be statistically significant. Results are pre-
sented as the mean value 6 SD.
RESULTS
Associations of CP seropositivity and IL-1 gene poly-
morphisms with CAD. Coronary artery disease was found
in 188 patients. Compared with 104 patients without CAD,
the 188 patients with CAD were older, predominantly men
and had higher rates of diabetes and smoking (Table 1). The
prevalence of CP IgG seropositivity was higher in patients
with CAD than without CAD (61 vs. 51%), but the
difference did not reach statistical significance. As for IL-1
gene polymorphisms, the genotype distributions in patients
with and without CAD did not deviate from the Hardy-
Weinberg equilibrium. The percentage of patients having
IL-1b C/C genotype was 22% in patients with CAD versus
13% without CAD. The percentage of patients carrying
IL-1Ra 2-repeat or 3-repeat allele was 7% in patients with
CAD versus 3% without CAD. The percentage of patients
who had the IL-1b C/C genotype and/or the IL-1Ra 2- or
3-repeat allele (IL-1 gene variants) was significantly higher
in patients with CAD than without CAD (29 vs. 16%, p ,
0.025). In multivariate analysis, the IL-1 gene variants were
found to be associated with CAD, but CP seropositivity was
not (Table 2).
Interaction between CP infection and IL-1 gene poly-
morphisms. Of the 292 patients, 168 had CP seropositivity,
and 72 had the IL-1 gene variants (IL-1b C/C genotype
and/or IL-1Ra 2- or 3-repeat allele). Between patients with
and without CP seropositivity, no significant difference was
found in the prevalence of CAD (68 vs. 59%) and MI (35 vs.
28%). To clarify the effects of IL-1 gene variants on CAD
associated with CP infection, patients were divided into four
groups according to the presence or absence of CP seroposi-
tivity and/or IL-1 gene variants. As shown in Figure 1, a
stepwise increase in CAD prevalence was seen depending on
CP seropositivity and/or IL-1 gene variants. In patients with
CP seropositivity, CAD prevalence was higher in those with
the variants than in those without the variants (83 vs. 64%, p ,
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence interval
CP 5 Chlamydia pneumoniae
ELISA 5 enzyme-linked immunosorbent assay
Ig 5 immunoglobulin
IL 5 interleukin
IL-1Ra 5 interleukin-1 receptor antagonist
MI 5 myocardial infarction
OR 5 odds ratio
PCR 5 polymerase chain reaction
Table 1. Clinical Characteristics and the Percentages of CP IgG Seropositivity and IL-1 Gene
Variants in Patients With and Without CAD
CAD (1)
(n 5 188)
CAD (2)
(n 5 104)
p
Value
Age (yrs) 64 6 9 60 6 10 ,0.001
Gender (male) 150 (80%) 58 (56%) ,0.001
Hypertension ($160/95 mm Hg or on medication) 92 (49%) 39 (38%) NS
Hyperlipidemia (TC .220 mg/dl or on medication) 91 (48%) 47 (45%) NS
TC (mg/dl) 201 6 37 204 6 38 NS
HDL-C (mg/dl) 48 6 13 57 6 16 ,0.001
Diabetes mellitus 48 (26%) 14 (13%) ,0.025
Smoking 136 (72%) 50 (48%) ,0.001
CP IgG titer 1.52 6 0.97 1.36 6 0.91 NS
Positive ($1.10) 115 (61%) 53 (51%) NS
IL-1b (2511) C/C genotype 42 (22%) 14 (13%) NS
IL-1Ra (intron 2) 2- or 3-repeat 14 (7%) 3 (3%) NS
IL-1b C/C and/or IL-1Ra 2- or 3-repeat 55 (29%) 17 (16%) ,0.025
Data are presented as the mean value 6 SD or the number (%) of patients.
CAD 5 coronary artery disease; CP 5 chlamydia pneumoniae; HDL-C 5 high-density lipoprotein cholesterol; Ig 5
immunoglobulin; IL 5 interleukin; IL-1Ra 5 interleukin-1 receptor antagonist; TC 5 total cholesterol.
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0.05), whereas, in patients without seropositivity, the difference
did not reach statistical significance between those with and
those without such variants (68 vs. 56%). Odds ratios (ORs)
for CAD were 1.4 (95% confidence interval [CI], 0.8 to 2.6) in
the group with CP seropositivity alone, 2.4 (0.9 to 6.6) in those
with the variants alone, and 4.3 (1.5 to 12.4) in those with
combined CP seropositivity and variants. In multivariate anal-
ysis, the IL-1 gene variants were associated with CAD in both
patients with and without CP seropositivity (Table 3).
Of the 188 patients with CAD, 93 had MI. The
diagnosis of either acute or old MI was given to 62 or 31
patients, respectively. Although 32 patients with CAD had
previously undergone coronary angioplasty, none had MI
due to restenosis. Interestingly, the prevalence of MI was
characteristically higher in the group with combined CP
seropositivity and IL-1 gene variants than in the other three
groups (p , 0.05) (Fig. 1), but there was no difference in
these three groups. The OR for MI was 2.7 (95% CI, 1.2 to
6.2) in the group with combined seropositivity and variants.
In multivariate analysis, the IL-1 gene variants were asso-
ciated with MI only in patients with CP seropositivity
(Table 4).
DISCUSSION
We could not find any association of CP seropositivity with
CAD, but IL-1 gene variants were associated with CAD.
However, a stepwise increase was observed in CAD preva-
lence depending on positive interaction between CP sero-
positivity and IL-1 gene variants, and the highest CAD
prevalence was seen in patients with combined seropositivity
and the variants. These suggest that IL-1 gene polymor-
phisms appear to influence the susceptibility to the athero-
genic effect of CP infection and that patients with such
variants are more likely to develop CAD associated with CP
infection. Interestingly, the IL-1 gene variants were associ-
ated with MI only in patients with CP seropositivity. Thus,
IL-1 gene polymorphisms may be modifying the CAD
Table 2. Contributing Factors for Coronary Artery Disease (Multiple Logistic Regression
Analysis in 292 Patients)
Variables b SE x2
p
Value OR (95% CI)
Age 0.076 0.02 24.0 ,0.001 1.08 (1.05–1.11)
HDL-C 20.043 0.01 18.2 ,0.001 0.96 (0.94–0.98)
IL-1 gene variants* 0.907 0.35 6.6 ,0.005 2.48 (1.24–4.94)
Gender (male) 0.856 0.35 5.9 ,0.025 2.35 (1.18–4.69)
Smoking 0.622 0.32 3.9 ,0.05 1.86 (1.00–3.46)
The dependent variable was coronary artery disease. The analysis included age, gender, hyperlipidemia, high density lipoprotein
cholesterol (HDL-C), diabetes mellitus, hypertension, smoking, interleukin (IL)-1 gene variants and Chlamydia pneumoniae
(CP) immunoglobulin (Ig)G seropositivity. *IL-1 gene variants were defined as the IL-1b C/C genotype and/or the
interleukin-1 receptor antagonist (IL-1Ra) 2- or 3-repeat allele.
CI 5 confidence interval; OR 5 odds ratio; SE 5 standard error.
Figure 1. Interaction between Chlamydia pneumoniae (CP) seropositivity and interleukin (IL)-1 gene variants in coronary artery disease (CAD) and
myocardial infarction (MI). Regarding CAD prevalence, a stepwise increase was seen depending on seropositivity and the variants. In contrast, MI
prevalence was characteristically high in the group with combined seropositivity and variants. The IL-1 gene variants were defined as IL-1b C/C genotype
and/or IL-1 receptor antagonist 2- or 3-repeat allele.
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process associated with CP infection, and patients with such
variants are more likely to develop MI in the process of
CAD with CP infection.
Infection of CP and CAD. Chlamydia pneumoniae was
often reported to be associated with CAD in seroepidemio-
logic studies (2–4). The association of CP with CAD was
strengthened by the detection of the organism within
atheroma using direct immunofluorescence and PCR
(17,18). A viable organism was also isolated from atheroma
(19). Muhlestein et al. (20) showed that CP infection
accelerates atherosclerosis in a rabbit model. However, the
potential contribution of CP to CAD remains controversial.
Two prospective studies (5,6) and one recent case-control
study (21) failed to show any association between CP
infection and CAD. We also found no association between
CP seropositivity and CAD. Individuals may vary in their
inflammatory response to CP infection, and only certain
individuals may be susceptible to the atherogenic effects of
CP infection, thus leading to the development of CAD.
The IL-1 gene polymorphisms. Recently, Lacoviello et al.
(13) reported IL-1b C/C genotype at 2511 to be associated
with MI. Nemetz et al. (22) reported that, in ulcerative
colitis, the IL-1b C/C genotype was associated with severe
bleeding and surgery and suggested that this polymorphism
plays a role in determining the course and severity of the
disease. However, the functional effect of this polymor-
phism remains unclear. Santtila et al. (23) found no signif-
icant difference in IL-1b production in vitro between alleles.
Francis et al. (14) reported that IL-1Ra 2-repeat allele in
intron 2 was associated with CAD, especially single-vessel
disease. They suggested that disease-modifying gene poly-
morphisms may determine the pattern of CAD. This
polymorphism has five alleles, from 2 to 6 repeats, and the
4-repeat allele is most common. The 2-repeat allele was
reported to be associated with an enhanced IL-1b produc-
tion in vitro (23), but its effect on IL-1Ra production
remains controversial (24,25). Although this polymorphism
is a marker of genetic susceptibility to ulcerative colitis (26),
it was reported to determine the course and severity of
diseases such as ulcerative colitis, alopecia and diabetic
nephropathy (26–28). Moreover, the presence of one copy
of the 2-repeat allele was suggested to be sufficient to affect
these diseases (27).
In our study, the IL-1b and IL-1Ra gene polymorphisms
were not independent factors for CAD. However, the
percentage of patients having IL-1b C/C genotype and/or
IL-1Ra 2- or 3-repeat allele was higher in CAD, and these
variants were associated with CAD. Moreover, these vari-
ants were associated with MI in patients with CP seropos-
itivity, suggesting that such IL-1 gene polymorphisms
modify the process of CAD associated with CP infection,
thereby leading to the development of MI.
Table 3. Contributing Factors for Coronary Artery Disease (Multiple Logistic Regression
Analysis in 168 Patients With CP Seropositivity and 124 Without CP Seropositivity)
Variables b SE x2
p
Value OR (95% CI)
CP seropositivity (1)
HDL-C 20.044 0.01 9.9 ,0.005 0.96 (0.93–0.98)
Age 0.049 0.02 6.2 ,0.025 1.05 (1.01–1.09)
Gender (male) 0.950 0.43 4.9 ,0.05 2.59 (1.11–6.02)
IL-1 gene variants* 1.038 0.49 4.4 ,0.05 2.82 (1.07–7.42)
CP seropositivity (2)
Age 0.114 0.03 17.7 ,0.001 1.12 (1.06–1.18)
Smoking 1.948 0.50 15.1 ,0.001 7.01 (2.62–18.8)
HDL-C 20.046 0.02 8.0 ,0.005 0.96 (0.93–0.99)
IL-1 gene variants* 1.075 0.55 3.8 ,0.05 2.93 (1.00–8.54)
The dependent variable was coronary artery disease. The analysis included age, gender, hyperlipidemia, high density lipoprotein
cholesterol (HDL-C), diabetes mellitus, hypertension, smoking, and interleukin (IL)-1 gene variants. *IL-1 gene variants were
defined as the IL-1b C/C genotype and/or the interleukin-1 receptor antagonist (IL-1Ra) 2- or 3-repeat allele.
CI 5 confidence interval; CP 5 Chlamydia pneumoniae; OR 5 odds ratio; SE 5 standard error.
Table 4. Contributing Factors for Myocardial Infaction (Multiple Logistic Regression Analysis
in 168 Patients With CP Seropositivity and 124 Without CP Seropositivity)
Variables b SE x2 p Value OR (95% CI)
CP seropositivity (1)
IL-1 gene variants* 1.028 0.38 7.5 ,0.025 2.80 (1.34–5.84)
HDL-C 20.031 0.01 5.1 ,0.025 0.97 (0.94–1.00)
CP seropositivity (2)
HDL-C 20.075 0.02 13.6 ,0.001 0.93 (0.90–0.95)
Smoking 0.993 0.49 4.1 ,0.05 2.70 (1.03–7.09)
The dependent variable was myocardial infarction. The analysis included age, gender, hyperlipidemia, high density lipoprotein
cholesterol (HDL-C), diabetes mellitus, hypertension, smoking, and interleukin (IL)-1 gene variants. *IL-1 gene variants were
defined as the IL-1b C/C genotype and/or the interleukin-1 receptor antagonist (IL-1Ra) 2- or 3-repeat allele.
CI 5 confidence interval; CP 5 Chlamydia pneumoniae; OR 5 odds ratio; SE 5 standard error.
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Interaction between CP infection and IL-1 gene poly-
morphisms. Genetic factors involved in CAD associated
with CP infection are unknown. Only one study (29)
showed HLA-DR-13a or -17 genotype in combination
with high lipoprotein (a) levels and CP seropositivity to be
more frequent in CAD. However, the difference compared
with controls was only significant in men with a lipoprotein
(a) level of $120 mg/dl. We showed the presence of a
stepwise increase in CAD prevalence depending on the
positive interaction between CP seropositivity and IL-1
gene variants, whereas, in addition, the highest CAD
prevalence occurred in patients with combined seropositivity
and variants. Our results suggest that the joint effect of CP
seropositivity and IL-1 gene variants seems to be additive
and that IL-1 gene polymorphisms influence susceptibility
to the atherogenic effects of CP infection. These findings
may provide a potential explanation for conflicting evidence
regarding the role of CP infection in CAD, because
genetically determined susceptibility to its atherogenic effect
may be an important factor in determining whether or not
it contributes to CAD.
We also showed that IL-1 gene variants were associated
with MI only in patients with CP seropositivity. Although
patients without CP seropositivity may have some other
infections, this modifying effect on the CAD process was
confined to patients with CP infection. Thus, IL-1 gene
polymorphisms may characteristically modify the process of
CAD associated with CP infection, leading to the develop-
ment of MI.
Study limitations. First, our study is cross-sectional; such a
study cannot establish causality. It shows some association
and is hypothesis-generating. Second, we did not have
healthy controls. We studied consecutive patients undergo-
ing angiography, who were divided into two groups with
and without CAD. Some patients without CAD had mild,
but not significant, stenosis. These may have caused some
selection bias and may have confounded the results. Third,
our study was in a Japanese population. The frequencies of
IL-1b C allele and IL-1Ra 2-repeat allele in healthy
Japanese were reported to be 0.54 and 0.03, respectively
(30), which were lower than those in healthy Caucasians
(0.62 to 0.65 and 0.24) (22,26). Our results may not be
applicable to other ethnic populations. However, the per-
centage of individuals susceptible to CAD associated with
CP infection may be higher in Caucasians than in Japanese.
Conclusions. The IL-1 gene polymorphisms were found
to play a role in the development of CAD, especially MI,
in patients with CP infection. The joint effect of CP
seropositivity and IL-1 gene variants on the development
of CAD seems to be additive, but the modifying effect of
these variants on CAD process may be limited only to
patients with CP seropositivity, leading to the develop-
ment of MI.
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